针对成人严重缺氧性缺血性脑病变的Edaravone试验:一项双盲,安慰剂控制的双盲研究
Saeed Razmeh1, Abdol Azim Karimi2, Amir Mohammad Dashti3
1Neurology Department, Yasuj University of Medical Science, Yasuj, Iran.
Journal of neurology
|March 15, 2026
概括
埃达拉在严重低毒性缺血性脑病变 (HIE) 患者中改善了意识. 然而,在这项短期研究中,它没有显著影响患者的结果或日常生活的独立性.
科学领域:
- 神经学 神经学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺氧性缺血性脑病变 (HIE) 是一种严重的脑损伤,具有显著的死亡率和长期残疾.
- 目前的治疗方法,如治疗性低温症并非普遍可用,辅助疗法正在研究中.
- 埃达拉是一种自由基清除剂,具有潜在的神经保护性质.
研究的目的:
- 评估Edaravone作为严重HIE的成年患者的辅助疗法的疗效.
- 评估Edaravone对意识,血液动力学稳定性和短期临床结果的影响.
- 这是第一个随机临床试验,用于探索Edaravone在严重HIE中的效果.
主要方法:
- 一项双盲临床试验,涉及72名患有严重HIE的成年患者,临床和放射诊断.
- 患者被随机分配到埃达拉组 (n=20) 和非埃达拉组 (n=52).
- 测量的关键参数包括格拉斯哥昏迷量表 (GCS),生命体征,巴特尔指数和患者结局 (死亡/出院).
主要成果:
- 埃达拉组在格拉斯哥昏迷量表 (GCS) 上显示出显著的短期改善 (p=0.001).
- 在患者整体结局 (p=0.863) 或出院患者的巴特尔得分 (P=0.557) 中,没有观察到群体之间的显著差异.
- 两组之间的温度有显著差异 (P=0.002),冠状动脉旁路移植是不同的并发症 (P=0.021).
结论:
- 埃达拉显示出在严重HIE的成年患者中改善短期意识水平的潜力.
- 该研究发现,埃达拉对患者的治疗结果或日常活动中的独立性没有显著的短期影响.
- 建议进行进一步的研究,以探索Edaravone在较轻的HIE病例和更长的随访期中的有效性.
相关概念视频
Acute Respiratory Failure-IV
683
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
683
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
532
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
717
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
717
Acute Respiratory Failure-II
1.4K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.4K
Acute Respiratory Failure-V
617
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
617
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
326
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
326


